Research programme: antibacterials - Entasis Therapeutics

Drug Profile

Research programme: antibacterials - Entasis Therapeutics

Alternative Names: ETX 0282; ETX 0282 CPDP; ETX 1317

Latest Information Update: 04 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Developer Entasis Therapeutics
  • Class Antibacterials; Small molecules
  • Mechanism of Action Beta lactamase inhibitors; Penicillin-binding protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Gram-negative infections

Most Recent Events

  • 07 Jun 2017 Entasis Therapeutics and CARB-X plan a clinical trial of ETX 0282 for Gram-negative infections
  • 07 Jun 2017 Preclinical trials in Gram-negative infections (Combination therapy) in USA (PO), before June 2017
  • 07 Jul 2015 Research programme: antibacterials - Entasis Therapeutics is available for licensing as of 07 Jul 2015. http://www.entasistx.com/partnering/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top